Trial Profile
A Phase Ib Clinical Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Metastatic Pancreatic Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Oct 2023
Price :
$35
*
At a glance
- Drugs Napabucasin (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- Sponsors Boston Biomedical; Sumitomo Dainippon Pharma Oncology; Sumitomo Pharma America
- 17 Jul 2020 Status changed from active, no longer recruiting to completed.
- 01 Jul 2020 According to a Sumitomo Dainippon Pharma Oncology media release, the Boston Biomedical has been merged with the Tolero Pharmaceuticals to form the Sumitomo Dainippon Pharma Oncology.
- 25 Mar 2019 Planned primary completion date changed from 1 Mar 2019 to 1 Mar 2020.